On the 2023 American Society for Medical Oncology Annual Assembly—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Most cancers Middle specialists will current analysis spanning survivorship, advances in remedies and scientific trials, how entry to most cancers care impacts outcomes, integrative drugs and extra.
Featured Fred Hutch shows and poster periods are listed beneath; for a full record of Fred Hutch analysis at ASCO and the dates and instances of shows, please go to our web site. For media inquiries at ASCO, please contact Claire Hudson at [email protected] You may observe our researchers on Twitter #ASCO23 and go to us at sales space #4023.
Equitable entry to most cancers care
Dr. Hiba Khan will current an oral summary assessing the affect of economic misery, as evidenced in credit score information, on most cancers survival. Researchers in Fred Hutch’s Hutchinson Institute for Most cancers Outcomes Analysis, or HICOR, discovered that sufferers with most cancers who skilled extreme antagonistic monetary occasions, reminiscent of third-party collections, delinquent mortgage funds, tax liens, foreclosures or repossessions inside two years of prognosis had been at greater threat for mortality after adjusting for sociodemographic and scientific components.
Extra analysis on well being fairness and entry contains:
- An evaluation displaying that antagonistic monetary occasions resulted in elevated well being care utilization and larger per-patient prices at finish of life, in a poster session from led by Dr. Natasha Kwendakwema of HICOR.
- Dr. Scott Ramsey and the HICOR crew adopted most cancers sufferers utilizing smartwatches and apps to observe signs and biometric knowledge throughout remedy. In a poster session, they share that in comparison with commercially-insured most cancers sufferers, financially fragile and Medicaid-insured sufferers had considerably greater common coronary heart charges, distinctive signs and repeat signs.
- A research revealing well being disparities in entry to molecular testing that inform using focused therapies in sufferers with superior stage non-small cell lung most cancers. In a poster session led by Dr. Lauren Shih, HICOR researchers discovered testing charges had been lowest amongst Hispanic sufferers, older sufferers, males and other people with Medicaid insurance coverage.
- A poster session, led by Qin Solar of HICOR, during which researchers discovered underuse of germline testing in sufferers with prostate, pancreas and ovarian cancers, regardless of guideline suggestions. Lack of germline testing not solely can have an effect on remedy, it’s additionally a missed alternative to establish genetic threat components in members of the family.
Medical trials and remedy advances
Dr. Noam Kopmar and colleagues sought to know the potential advantage of including an antibody drug conjugate to frontline remedy to deal with sufferers with relapsed or refractory B-cell acute lymphoblastic leukemia or lymphoma. In an oral presentation, Dr. Kopmar will clarify findings that including the antibody drug was not solely protected, however response charges in sufferers had been among the many highest reported so far and plenty of sufferers had been capable of proceed to bone marrow transplant.
In a SWOG Most cancers Analysis Community evaluation, offered in an oral summary by Dr. Megan Othus, a analysis crew discovered {that a} frequent system for measuring tumor development in scientific trials didn’t adequately correspond to outcomes in sufferers with uncommon cancers handled with checkpoint inhibitors within the S1609 DART trial. These findings are in line with related research of using this measuring system in sufferers handled with chemotherapy.
In an oral presentation, Dr. Shailender Bhatia will current findings from a Section 2 scientific trial in metastatic Merkel cell carcinoma sufferers that assessed nivolumab monotherapy and nivolumab plus ipilimumab mixture in two non-randomized cohorts respectively. The outcomes don’t recommend extra profit from nivolumab plus ipilimumab on this affected person inhabitants, opposite to a latest publication that had reported 100% response price with mixture remedy.
Consultants will share extra from the next remedy research:
- A five-year observe up research combining normal of care plus a checkpoint inhibitor in sufferers with diffuse massive B cell lymphoma, supporting potential inclusion of checkpoint inhibitors in first line DLBCL remedy and exploring the function of PD-L1 as a predictive biomarker in a poster session led by Dr. Carrie Ho.
- How combining hypofractionated radiation with checkpoint inhibitors could profit sufferers with metastatic salivary gland cancers, in a poster session led by Dr. Cristina Rodriguez.
- Outcomes from a Section 1 research testing the mix of anti-CD73 and anti-PD-L1 monoclonal antibodies to deal with metastatic pancreatic ductal adenocarcinoma that discovered the routine was protected and indicated a pattern towards improved outcomes, led by Dr. Andrew Coveler in a poster session.
- Dr. Laura Samples and collaborators characterised the challenges in utilizing CAR T-cell remedy to deal with sufferers with relapsed or refractory Burkitt lymphoma, a uncommon and extremely aggressive B-cell lymphoma, in a poster session.
- Outcomes from a survey performed by an American Society of Medical Oncology and Buddies of Most cancers Analysis activity drive, chaired by Dr. Joseph Unger, confirmed that methods reminiscent of distant distribution of oral remedy, distant consenting and distant symptom monitoring had been generally adopted by main most cancers scientific trial sponsors through the COVID-19 pandemic. Findings might be offered in a poster session.
- Led by Dr. Bart Scott, in a poster session, researchers discovered that general survival charges for sufferers with acute myeloid leukemia weren’t impacted through the pandemic, however that elevated COVID-19 charges within the U.S. correlated with fewer transfusions, in-person visits and assessments for stem cell transplant.
- Components related to sturdy response from a five-year observe up in sufferers who acquired CD19 CAR T-cell remedy for relapsed and refractory continual lymphocytic leukemia, in a poster session led by Dr. Emily Liang.
Survivorship
Pediatric most cancers sufferers who obtain sure therapies are at an elevated threat of coronary heart illness later in life. Dr. Eric Chow will current an oral summary of a Youngsters’s Oncology Group research that discovered a greater methodology to foretell which pediatric most cancers sufferers will develop coronary heart illness years after remedy. Prediction fashions that incorporate standard coronary heart measurements could possibly precisely establish childhood most cancers sufferers at excessive threat of creating coronary heart illness inside 2-5 years, giving care groups a possible window of alternative to supply remedies that may gradual or cease coronary heart illness development.
Precision oncology
Dr. Manoj Menon will share insights in a poster session from a research that performed molecular testing on breast most cancers tumors from sufferers on the Uganda Most cancers Institute. The analysis crew discovered a various vary of mutations and prevalence of BRCA1, BRCA2 and PIK3CA mutations that had been significantly greater than in different documented populations. This knowledge might inform wider use of focused therapies in sub-Saharan Africa, the place breast most cancers is the commonest most cancers, and make the case for together with focused most cancers therapies within the World Well being Group’s Mannequin Record of Important Medicines.
Dr. Ruben Raychaudhuri and collaborators investigated focused therapies for folks with metastatic castration resistant prostate most cancers (mCRPC) with DNA harm restore alterations in two research. One poster session will discover how mutations in DNA harm restore genes could have an effect on PSMA expression and response to PSMA focused radioligand remedy. A second poster session will element two-year observe up outcomes from a single arm pilot research additionally centered on sufferers with DNA harm restore alterations. On this research, researchers discovered that the addition of the DNA damaging agent carboplatin to straightforward of care docetaxel considerably improved response charges.
Integrative drugs
In sufferers with non-muscle-invasive bladder most cancers, researchers examined the feasibility and efficacy of in-office acupuncture to scale back ache and urinary signs throughout induction intravesical Bacillus Calmette-Guerin (BCG). In a poster session, led by Dr. Sarah Psutka, researchers noticed enhancements in urinary signs and a suggestion of a discount in ache scores over successive remedies within the sufferers who acquired acupuncture.
